Hangover and Residual Zopiclone Effect on Spatial Perception
NCT ID: NCT03632408
Last Updated: 2018-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
16 participants
INTERVENTIONAL
2018-09-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Delayed-release Bedtime Caffeine and Sleep Inertia Symptoms Immediately Upon Awakening
NCT04975360
Hypnotic Intake and Motor and Cognitive Performances at High Altitude
NCT02778659
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
NCT00283790
Hypnotic Medications and Memory: Effect of Drug Exposure During the Night
NCT01159652
Brief Intervention for Sleep Medication Misuse Among Elderly
NCT06032715
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zopiclone
Oral, single dose, 7.5 mg
hangover
as per subjects choice to consume alcohol
Placebo oral capsule
oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* likely to experience and predict alcohol hangover within the next five weeks
* no childbearing potential of negative pregnancy test at screening
* a valid driving license
Exclusion Criteria
* infection with HCV, HBV or HIV
* a medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
* suspected or current drug or alcohol abuse
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Turku
OTHER
Petri Vainio
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Petri Vainio
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Petri J Vainio, MD
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teutori clinical trial facility
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T271
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.